ADMA Biologics Inc. (ADMA)
| Market Cap | 477.15M |
| Revenue (ttm) | 110.07M |
| Net Income (ttm) | -73.14M |
| Shares Out | 196.36M |
| EPS (ttm) | -0.49 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,990,437 |
| Open | 2.28 |
| Previous Close | 2.26 |
| Day's Range | 2.26 - 2.48 |
| 52-Week Range | 1.01 - 2.92 |
| Beta | 0.92 |
| Analysts | Buy |
| Price Target | 4.76 (+95.9%) |
| Earnings Date | Nov 8, 2022 |
About ADMA
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposur... [Read more...]
Financial Performance
In 2021, ADMA Biologics's revenue was $80.94 million, an increase of 91.72% compared to the previous year's $42.22 million. Losses were -$71.65 million, -5.41% less than in 2020.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for ADMA stock is "Buy." The 12-month stock price forecast is 4.76, which is an increase of 95.88% from the latest price.
News
7 A-Rated Stocks to Buy for Less Than $10
Some stocks under $10 are cheap for a reason, but there are other stocks under $10 that are solid long-term investments. There are all sorts of equities from which to choose when building your portfolio.
Why ADMA Biologics Stock Triumphed on Thursday
Investors were pleasantly surprised by the company's latest set of quarterly figures.
Adma Biologics (ADMA) Reports Q2 Loss, Tops Revenue Estimates
Adma Biologics (ADMA) delivered earnings and revenue surprises of 22.22% and 8.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
ADMA Biologics Announces Second Quarter 2022 Financial Results and Provides Business Update
2Q2022 Total Revenues Were $33.9 Million, a 90% Y-o-Y Increase
Adma Biologics (ADMA) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Adma Biologics (ADMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ADMA Biologics to Report Second Quarter 2022 Financial Results on August 10, 2022
Conference Call Scheduled for August 10, 2022, at 4:30 p.m. ET Conference Call Scheduled for August 10, 2022, at 4:30 p.m. ET
ADMA Biologics Announces Addition to the Russell 2000® Index
Ramsey, N.J. and Boca Raton, Fla., June 21, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufa...
Adma Biologics (ADMA) Reports Q1 Loss, Tops Revenue Estimates
Adma Biologics (ADMA) delivered earnings and revenue surprises of -25% and 9.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
ADMA Biologics Announces First Quarter 2022 Financial Results and Provides Business Update
First Quarter 2022 Total Revenues Were Approximately $29.1 Million, an 81% Increase Over First Quarter 2021
ADMA Biologics to Report First Quarter 2022 Financial Results on May 11, 2022
Conference Call Scheduled for May 11, 2022 at 4:30 p.m. ET Conference Call Scheduled for May 11, 2022 at 4:30 p.m. ET
ADMA Announces Live Poster Presentation and Symposium on Real-World Experience with ASCENIV™ at CIS 2022
RAMSEY, N.J. and BOCA RATON, Fla., April 01, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manuf...
ADMA Biologics' Q4 Top-Line Surpass Estimates, Concludes $175M Debt Refinancing
ADMA Biologics Inc (NASDAQ: ADMA) closed a debt refinancing with Hayfin Capital Management of $150 million, and up to an additional $25 million tied to specific revenue targets during 2022. The first tr...
ADMA Biologics Announces FDA Approval of Extended Shelf Life for ASCENIV™ & BIVIGAM® from 24 to 36 Months
Approval of 36-month shelf life encompasses all ASCENIV & BIVIGAM vial sizes, production scales, as well as internal and external fill-finishing
Adma Biologics (ADMA) Reports Q4 Loss, Tops Revenue Estimates
Adma Biologics (ADMA) delivered earnings and revenue surprises of 10% and 1.47%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
ADMA Biologics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update, Including ...
Full Year 2021 Total Revenues of Approximately $81 Million, a 92% Increase Over Full Year 2020
ADMA Biologics to Report Fourth Quarter and Full Year 2021 Financial Results on March 24, 2022
Conference Call Scheduled for March 24, 2022 at 4:30 p.m. ET Conference Call Scheduled for March 24, 2022 at 4:30 p.m. ET
ADMA BioCenters Receives FDA Approval for its Fifth Plasma Collection Center, Located in Conyers, GA
FDA approval supports corporate goal of plasma supply self-sufficiency and ongoing revenue growth Company positioned to meet or exceed target of 10 or more FDA-approved plasma collection centers by yea...
ADMA Biologics Shares Gain As Interim Q4 Sales Beat Expectation
ADMA Biologics Inc (NASDAQ: ADMA) expects Q4 Sales of approximately $26 million, compared to $14 million a year ago and better than the consensus of $21.76 million. The preliminary results represent th...
ADMA Biologics Announces Record Preliminary Fourth Quarter and Full Year 2021 Revenues and Provides 2022 Business Update
Fourth Quarter 2021 Preliminary Unaudited Total Revenues of Approximately $26 Million, the Highest Quarterly Revenue for the Company Since Inception
ADMA BioCenters Receives FDA Approval for its Fourth Plasma Collection Center Located in Goose Creek, SC
FDA approval positions Company to meet or exceed target of ten or more FDA-licensed plasma collection centers by year-end 2023 FDA approval positions Company to meet or exceed target of ten or more FDA-...
ADMA Biologics Adopts Limited Duration Stockholder Rights Plan
RAMSEY, N.J. and BOCA RATON, Fla., Dec. 21, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and dev...
Implied Volatility Surging for ADMA Biologics (ADMA) Stock Options
Investors need to pay close attention to ADMA Biologics (ADMA) stock based on the movements in the options market lately.
ADMA Biologics Provides Update on Global Intellectual Property Portfolio
Extends Existing U.S. Patent with Granted European Patent for Treatment and Prevention of S. Pneumococcal Infections with a Hyperimmune Globulin
ADMA Biologics Senior Vice President of Plasma Services Cyndi Tolman Elected to PPTA Source Board of Directors
RAMSEY, N.J. and BOCA RATON, Fla., Nov. 17, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufa...